Abstract: Genes encoding microbial ?-glucuronidase and protein that is secreted and its uses are provided.

Abstract: The invention provides a SHINC-2 polynucleotide, which can be a nucleic acid encoding all or a portion of a SHINC-2 protein, or a complementary polynucleotide or antisense polynucleotide. The invention provides a SHINC-2 polypeptide, which can be a full-length SHINC-2 protein or a fragment thereof or an analog or homolog thereof. Desirably, the SHINC-2 polypeptide modulates apoptosis. The invention provides an antibody that specifically binds a SHINC-2 polypeptide. The invention provides diagnostic methods. For example, the invention affords a method for identifying compounds that modulate apoptosis. The invention provides a method for detecting or evaluating the prognosis of a cancer. The invention provides diagnostic compositions for detection of cancer. The invention provides a method of modulating apoptosis or treating or preventing a cancer, tumor growth and/or metastasis by administration of an agent that modulates the expression and/or activity of SHINC-2.

Abstract: The invention uses the power of display selection methods to screen libraries of human immunoglobulin genes from nonhuman transgenic animals expressing human immunoglobulins. Such screening produces unlimited numbers of high affinity human antibodies to any target of interest.

Abstract: The invention relates to a method for producing a protein of interest comprising transforming a target insect with a non-viral expression system that expresses the protein in the insect larvae, breeding the insect to produce larvae, culturing the larvae and isolating the protein from the larvae.

Abstract: The invention relates to the identification and disruption of essential fungal specific genes isolated in the yeast pathogen Candida albicans namely CaKRE5, CaALR1, and CaCDC24 and to the use thereof in antifungal diagnosis and as essential antifungal targets in a fungal species for antifungal drug discovery. More specifically, the invention relates to the CaKRE5, CaALR1, and CaCDC24 genes, to their use to screen for antifungal compounds and to the drugs identified by such.

Abstract: The invention provides a transgenic pig having incorporated into its genome a HSP70 gene or fragment thereof, whereby the transgenic pig overexpresses HSP70. The transgenic pig of the invention can be used in the production of HSP in large quantities, as a xenograft source for transplantation and as an animal model close to human for illustrating the protective roles of HSP. Furthermore, the transgenic pig of the invention has a better meat quality and exhibits an increased growth rate and a reduced backfat thickness.

Abstract: The invention provides a transgenic animal having within its genome a transgene construct for gastrointestinal tract specific expression of a protein. In a preferred embodiment, the protein is a phytase or a homologue thereof. Such proteins may be heterologous and may be specifically expressed in the salivary gland of the animal by operably linking the nucleic acid sequence encoding the protein with regulatory sequence including a salivary gland protein promoter/enhancer. Also provided are methods of expressing and producing proteins using such nucleic acid constructs. Further, antibodies specific to such proteins and immunological diagnostic kits are also provided.

Abstract: Described are methods for identifying targets in RNA molecules based on differences in RNA secondary structure related to sequence variances between different allelic forms. Also described are methods for identifying or developing small molecules which can be used to modulate a target RNA by creation of protein-small-molecule-RNA complexes, as well as compositions which include such small molecules and methods of using those small molecules and compositions.

Abstract: Compositions and methods for the diagnosis, prevention and treatment of immune states and disorders amenable to treatment through modulation of T cell activation are provided. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding B7 proteins.

Abstract: The present invention relates to novel transcription control elements derived from a mouse eosinophil peroxidase gene. Such transcription control elements may comprise isolated polynucleotides, expression cassettes, vectors, recombinant cells, and transgenic animals, as described herein.

Abstract: Disclosed are methods for identifying nematodes having enhanced susceptibility to a pathogen; for identifying pathogen defense response genes; and for identifying compounds that enhances a host's defense response to a pathogen.

Abstract: Compositions and methods for delivering GDNF to skeletal muscles to result in a therapeutic effect are disclosed. The compositions and methods use adeno-associated virus (AAV)-based gene delivery systems. The methods are useful for treating motoneuron diseases, such as amyotrophic lateral sclerosis (ALS).

Abstract: The present invention provides an advance in phage display technology by permitting the uncoupling of the propagation of phages containing inserted sequences encoding heterologous polypeptides from the expression of said polypeptides. The invention provides phage constructs and methods for their use to permit phage coat protein expression, and thus phage propagation, in the absence of display of heterologous polypeptides, which may be expressed as a fusion with said coat protein in a regulated manner.

Abstract: Compositions and methods are described for nucleic acid formulation for gene delivery. A new class of low molecular weight condensing agents, namely aromatic amino acid—containing peptides, are described for use in receptor-mediated and nonreceptor-mediated gene delivery, both in vivo and in vitro.

Abstract: Presented are ways to address the problem of replication competent adenovirus in adenoviral production for use with, for example, gene therapy. Packaging cells having no overlapping sequences with a selected vector are suited for large scale production of recombinant adenoviruses. A system for use with the invention produces replication defective adenovirus. The system includes a primary cell containing a nucleic acid based on or derived from adenovirus and an isolated recombinant nucleic acid molecule for transfer into the primary cell. The isolated recombinant nucleic acid molecule is based on or derived from an adenovirus, has at least one functional encapsidation signal and at least one functional Inverted Terminal Repeat, and lacks overlapping sequences with the nucleic acid of the cell. Otherwise, the overlapping sequences would enable homologous recombination leading to replication competent adenovirus in the primary cell into which the isolated recombinant nucleic acid molecule is to be transferred.

Abstract: The present invention relates to a method for treating bone pathologies comprising delivering a viral or non-viral delivery vehicle comprising genetic information (e.g. a transgene) encoding a therapeutic osteoinductive factor to target cells in vivo enabling the cells to produce the osteoinductive factor at the site of the bone pathology. The delivery is achieved by a simplified method which does not require cumbersome ex vivo techniques or additional matrix or scaffolding agents. Such viral and non-viral delivery vehicles of the present invention are derived from the following nonlimiting examples: adenoviruses, adeno-associated viruses, retroviruses, herpes simplex viruses, liposomes, and plasmids. The osteoinductive factors include, but are not limited to, growth factors, cytokines, growth factor inhibitors and cytokine inhibitors.

Abstract: Methods are disclosed for delivering a heterologous gene to a cell body of a neuron by contacting a muscle tissue innervated by the neuron with a viral vector comprising a heterologous gene, wherein the viral vector enters said neuron and is retrogradely moved to the cell body. Additionally, methods for expressing secreted proteins from a nerve cell body as well as methods for treating neurodegenerative disorders such as amyotrophic lateral sclerosis are described.

Abstract: Expression constructs using an inducible amplification system to drive expression of a therapeutic gene or other genes of interest in mammalian cells are provided, as well as methods of using the same.

Abstract: The present invention relates to water-stress tolerance, in particular to the OSR-1 (osmotic stress resistant-1) protein, and nucleic acids encoding the OSR-1 protein. The present invention provides assays for the detection of OSR-1, and polymorphisms and mutations associated with water stress tolerance. In particular, the present invention relates to compositions comprising small interfering RNA duplexes (RNAi), or vectors that encode dsRNA, that inhibit expression of the OSR-1 gene (e.g. by targeting OSR-1 mRNA), and methods of using these compositions to impair deleterious nematodes.

Abstract: The present invention provides for a recombinant insect larvae and a process of manufacturing proteins utilizing insect larvae that allows for the selection of individual larvae for harvest at the point of their optimal expression of a protein of interest. This invention also provides for a process to manufacture proteins in larvae that does not require synchronization of the infection, growth and harvest larvae to optimally manufacture a protein of interest. The invention further provides for a process of producing interleukin-2 in larvae.